I don’t fully understand the behavior of Aspreva Pharmaceuticals’ stock price. There has been no change in the company’s performance or analyst expectations, the company recently got its flagship product approved for a new use, and earnings beat analyst expectations. There doesn’t seem to be any explanation for the abysmal performance of this stock. This stock dragged down my portfolio more than any other stock.